NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer

Update your browser to view ScienceDirect correctly.

Your technical details and browser version:

Request ID: 95a02d68ce7f679f-LAX IP: 47.97.18.252 UTC time: 2025-07-04T17:00:11+00:00 Browser: Mozilla/5.0 (X11; U; Linux x86_64; en-US; rv:1.9.1.4) Gecko/20091030 Gentoo Firefox/3.5.4